Safety study of aflibercept eye injections in Japanese glaucoma patients
Treatments studied
Part of Eyes & vision clinical trials.
This trial checks how safe aflibercept (eye injection) is for Japanese people with neovascular glaucoma. You may be able to join if you already received aflibercept treatment under the approved Japanese instructions and have the correct diagnosis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with neovascular glaucoma (a specific type of glaucoma).
- You have already received aflibercept injections into the eye using the approved Japanese instructions.
- Your situation must match what is allowed on the approved label (no safety reasons that would block use).
- You must not have glaucoma or another eye condition that is not neovascular glaucoma.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows patients receiving aflibercept 8 mg injections in the eye to treat wet age-related macular degeneration (nAMD), a condition that blurs central vision. The goal is to understand how well this treatment works and its safety in routine medical practice.
This study compares two eye injection treatments for wet age-related macular degeneration (AMD), a condition that causes vision loss. The trial aims to see if the new drug GNR-139 works as well as the standard treatment Eylea.
This trial tests if switching to a higher dose of aflibercept (Eylea) can help people with wet age-related macular degeneration (AMD) who need frequent eye injections. If you've been on other anti-VEGF injections for over a year and still need them more often than every 12 weeks, this study might offer a new option.
This trial tests a new eye injection called AIV007 to see if it can safely treat wet age-related macular degeneration (AMD). It's for people who have already had treatment that worked before, and it might offer a different way to deliver the medicine.
This study tests a new higher-dose version of an eye injection called aflibercept (Eylea) for people with a specific type of wet age-related macular degeneration called polypoidal choroidal vasculopathy (PCV). The goal is to see if this treatment is effective, long-lasting, and safe, and it may help improve or preserve your vision.
This study looks at how well the higher-dose eye injection aflibercept 8 mg works in people who have already had at least three earlier anti-VEGF injections for wet age-related macular degeneration (wet AMD) or diabetic macular edema (DME). It tests if switching to this stronger dose is safe and effective in real-world care.
Hear when a new Neovascular Glaucoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.